Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function
Bisphosphonates have been shown to attenuate ectopic calcification in experimental uremia. While they are known to reduce bone turnover, the effects on endochondral bone formation have not yet been addressed. To address this issue, we administered male Sprague-Dawley rats weekly subcutaneous injecti...
Gespeichert in:
| Veröffentlicht in: | Pediatric nephrology (Berlin, West) West), 2011, Vol.26 (1), p.111-117 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 117 |
|---|---|
| container_issue | 1 |
| container_start_page | 111 |
| container_title | Pediatric nephrology (Berlin, West) |
| container_volume | 26 |
| creator | Fischer, Dagmar-Christiane Jensen, Claudia Rahn, Anja Salewski, Birgit Kundt, Günther Behets, Geert J. D’Haese, Patrick Haffner, Dieter |
| description | Bisphosphonates have been shown to attenuate ectopic calcification in experimental uremia. While they are known to reduce bone turnover, the effects on endochondral bone formation have not yet been addressed. To address this issue, we administered male Sprague-Dawley rats weekly subcutaneous injections of either vehicle or ibandronate (1.25 μg/kg body weight) for a total of 10 weeks. The rats were randomly allocated into one of four groups: (1) vehicle-treated, sham-operated rats; (2) ibandronate-treated, sham-operated rats; (3) vehicle-treated, 5/6 nephrectomized rats; (4) ibandronate-treated, 5/6 nephrectomized rats. Bones were double labeled with tetracycline and demeclocycline in vivo, and tibiae were removed for analysis. Weight gain was similar in all groups. Ibandronate reduced body length gain and tibial growth rate in the sham-operated animals but not in the rats showing chronic renal failure (CRF). The height of the proliferative zone of the epiphyseal growth plate was reduced in the ibandronate-treated controls and tended to be reduced in CRF rats. A significant correlation between tibial growth rate and height of the proliferative zone was observed. Mineral apposition rates were significantly reduced in ibandronate-treated, sham-operated rats and tended to be reduced in CRF rats. In conclusion, ibandronate interferes with tibial growth and bone mineralization in young rats with normal and reduced renal function. |
| doi_str_mv | 10.1007/s00467-010-1660-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_814465049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A331348947</galeid><sourcerecordid>A331348947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c565t-353eb3b4f15f8f3915dbd5de5ba13e0127ae64e5db5c27fc43d23dcfa6dd54a3</originalsourceid><addsrcrecordid>eNp9kk9LHTEUxUOp1KftB-imDBTabsYmk2T-LEXaKgjduHAXMsnNe5GZxCYziP30vePTquVVsgi593cu3JNDyHtGjxilzddMqaibkjJasrqmpXxFVkzwqmRde_marGjHWUkFu9wnBzlfUUpb2dZvyH5FO8lrLlZEn_U62BSDnqDQzoGZctHHAMU6xZtpU2C3GH2ApAf_W08-hsKHImnEbjz2Q0yjHu6wBHY2sNwBK24OZsHfkj2nhwzv7u9DcvH928XJaXn-88fZyfF5aWQtp5JLDj3vhWPStY53TNreSguy14wDZVWjoRaAVWmqxhnBbcWtcbq2VgrND8nn7djrFH_NkCc1-mxgGHSAOGfVMiFqSUWH5JcXSSZki-5IIRD9-A96FeeE2yGFFsqukYI-Ums9gPLBxSlpswxVx5wzLtpONEiVO6g13FmLhjuP5Wf80Q4ej4XRm52CT08EG9DDtMlxmJdPyM9BtgVNijkncOo6-VGnW1xKLcFS22ApurwxWEqi5sO9E3M_gv2reEgSAtUWyNgKa0hPrfrf1D9C-dZ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1095597540</pqid></control><display><type>article</type><title>Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Fischer, Dagmar-Christiane ; Jensen, Claudia ; Rahn, Anja ; Salewski, Birgit ; Kundt, Günther ; Behets, Geert J. ; D’Haese, Patrick ; Haffner, Dieter</creator><creatorcontrib>Fischer, Dagmar-Christiane ; Jensen, Claudia ; Rahn, Anja ; Salewski, Birgit ; Kundt, Günther ; Behets, Geert J. ; D’Haese, Patrick ; Haffner, Dieter</creatorcontrib><description>Bisphosphonates have been shown to attenuate ectopic calcification in experimental uremia. While they are known to reduce bone turnover, the effects on endochondral bone formation have not yet been addressed. To address this issue, we administered male Sprague-Dawley rats weekly subcutaneous injections of either vehicle or ibandronate (1.25 μg/kg body weight) for a total of 10 weeks. The rats were randomly allocated into one of four groups: (1) vehicle-treated, sham-operated rats; (2) ibandronate-treated, sham-operated rats; (3) vehicle-treated, 5/6 nephrectomized rats; (4) ibandronate-treated, 5/6 nephrectomized rats. Bones were double labeled with tetracycline and demeclocycline in vivo, and tibiae were removed for analysis. Weight gain was similar in all groups. Ibandronate reduced body length gain and tibial growth rate in the sham-operated animals but not in the rats showing chronic renal failure (CRF). The height of the proliferative zone of the epiphyseal growth plate was reduced in the ibandronate-treated controls and tended to be reduced in CRF rats. A significant correlation between tibial growth rate and height of the proliferative zone was observed. Mineral apposition rates were significantly reduced in ibandronate-treated, sham-operated rats and tended to be reduced in CRF rats. In conclusion, ibandronate interferes with tibial growth and bone mineralization in young rats with normal and reduced renal function.</description><identifier>ISSN: 0931-041X</identifier><identifier>EISSN: 1432-198X</identifier><identifier>DOI: 10.1007/s00467-010-1660-5</identifier><identifier>PMID: 20953634</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Animals ; Bisphosphonates ; Body weight ; Bone Density Conservation Agents - pharmacology ; Bone Development - drug effects ; Calcification ; Calcification, Physiologic - drug effects ; Calcium - blood ; Chronic kidney failure ; Diphosphonates - pharmacology ; Drinking water ; Drug dosages ; Growth ; Growth Plate - drug effects ; Ketamine ; Kidney - physiology ; Kidney - surgery ; Kidney diseases ; Kidney Failure, Chronic - physiopathology ; Male ; Medical research ; Medicine ; Medicine & Public Health ; Metabolism ; Mineralization ; Nephrectomy ; Nephrology ; Original Article ; Osteoporosis ; Parathyroid Hormone - blood ; Pediatrics ; Phosphates - blood ; Phosphonates ; Rats ; Rats, Sprague-Dawley ; Uremia ; Urology</subject><ispartof>Pediatric nephrology (Berlin, West), 2011, Vol.26 (1), p.111-117</ispartof><rights>IPNA 2010</rights><rights>COPYRIGHT 2011 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c565t-353eb3b4f15f8f3915dbd5de5ba13e0127ae64e5db5c27fc43d23dcfa6dd54a3</citedby><cites>FETCH-LOGICAL-c565t-353eb3b4f15f8f3915dbd5de5ba13e0127ae64e5db5c27fc43d23dcfa6dd54a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00467-010-1660-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00467-010-1660-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20953634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fischer, Dagmar-Christiane</creatorcontrib><creatorcontrib>Jensen, Claudia</creatorcontrib><creatorcontrib>Rahn, Anja</creatorcontrib><creatorcontrib>Salewski, Birgit</creatorcontrib><creatorcontrib>Kundt, Günther</creatorcontrib><creatorcontrib>Behets, Geert J.</creatorcontrib><creatorcontrib>D’Haese, Patrick</creatorcontrib><creatorcontrib>Haffner, Dieter</creatorcontrib><title>Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function</title><title>Pediatric nephrology (Berlin, West)</title><addtitle>Pediatr Nephrol</addtitle><addtitle>Pediatr Nephrol</addtitle><description>Bisphosphonates have been shown to attenuate ectopic calcification in experimental uremia. While they are known to reduce bone turnover, the effects on endochondral bone formation have not yet been addressed. To address this issue, we administered male Sprague-Dawley rats weekly subcutaneous injections of either vehicle or ibandronate (1.25 μg/kg body weight) for a total of 10 weeks. The rats were randomly allocated into one of four groups: (1) vehicle-treated, sham-operated rats; (2) ibandronate-treated, sham-operated rats; (3) vehicle-treated, 5/6 nephrectomized rats; (4) ibandronate-treated, 5/6 nephrectomized rats. Bones were double labeled with tetracycline and demeclocycline in vivo, and tibiae were removed for analysis. Weight gain was similar in all groups. Ibandronate reduced body length gain and tibial growth rate in the sham-operated animals but not in the rats showing chronic renal failure (CRF). The height of the proliferative zone of the epiphyseal growth plate was reduced in the ibandronate-treated controls and tended to be reduced in CRF rats. A significant correlation between tibial growth rate and height of the proliferative zone was observed. Mineral apposition rates were significantly reduced in ibandronate-treated, sham-operated rats and tended to be reduced in CRF rats. In conclusion, ibandronate interferes with tibial growth and bone mineralization in young rats with normal and reduced renal function.</description><subject>Animals</subject><subject>Bisphosphonates</subject><subject>Body weight</subject><subject>Bone Density Conservation Agents - pharmacology</subject><subject>Bone Development - drug effects</subject><subject>Calcification</subject><subject>Calcification, Physiologic - drug effects</subject><subject>Calcium - blood</subject><subject>Chronic kidney failure</subject><subject>Diphosphonates - pharmacology</subject><subject>Drinking water</subject><subject>Drug dosages</subject><subject>Growth</subject><subject>Growth Plate - drug effects</subject><subject>Ketamine</subject><subject>Kidney - physiology</subject><subject>Kidney - surgery</subject><subject>Kidney diseases</subject><subject>Kidney Failure, Chronic - physiopathology</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Mineralization</subject><subject>Nephrectomy</subject><subject>Nephrology</subject><subject>Original Article</subject><subject>Osteoporosis</subject><subject>Parathyroid Hormone - blood</subject><subject>Pediatrics</subject><subject>Phosphates - blood</subject><subject>Phosphonates</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Uremia</subject><subject>Urology</subject><issn>0931-041X</issn><issn>1432-198X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kk9LHTEUxUOp1KftB-imDBTabsYmk2T-LEXaKgjduHAXMsnNe5GZxCYziP30vePTquVVsgi593cu3JNDyHtGjxilzddMqaibkjJasrqmpXxFVkzwqmRde_marGjHWUkFu9wnBzlfUUpb2dZvyH5FO8lrLlZEn_U62BSDnqDQzoGZctHHAMU6xZtpU2C3GH2ApAf_W08-hsKHImnEbjz2Q0yjHu6wBHY2sNwBK24OZsHfkj2nhwzv7u9DcvH928XJaXn-88fZyfF5aWQtp5JLDj3vhWPStY53TNreSguy14wDZVWjoRaAVWmqxhnBbcWtcbq2VgrND8nn7djrFH_NkCc1-mxgGHSAOGfVMiFqSUWH5JcXSSZki-5IIRD9-A96FeeE2yGFFsqukYI-Ums9gPLBxSlpswxVx5wzLtpONEiVO6g13FmLhjuP5Wf80Q4ej4XRm52CT08EG9DDtMlxmJdPyM9BtgVNijkncOo6-VGnW1xKLcFS22ApurwxWEqi5sO9E3M_gv2reEgSAtUWyNgKa0hPrfrf1D9C-dZ4</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Fischer, Dagmar-Christiane</creator><creator>Jensen, Claudia</creator><creator>Rahn, Anja</creator><creator>Salewski, Birgit</creator><creator>Kundt, Günther</creator><creator>Behets, Geert J.</creator><creator>D’Haese, Patrick</creator><creator>Haffner, Dieter</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2011</creationdate><title>Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function</title><author>Fischer, Dagmar-Christiane ; Jensen, Claudia ; Rahn, Anja ; Salewski, Birgit ; Kundt, Günther ; Behets, Geert J. ; D’Haese, Patrick ; Haffner, Dieter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c565t-353eb3b4f15f8f3915dbd5de5ba13e0127ae64e5db5c27fc43d23dcfa6dd54a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Bisphosphonates</topic><topic>Body weight</topic><topic>Bone Density Conservation Agents - pharmacology</topic><topic>Bone Development - drug effects</topic><topic>Calcification</topic><topic>Calcification, Physiologic - drug effects</topic><topic>Calcium - blood</topic><topic>Chronic kidney failure</topic><topic>Diphosphonates - pharmacology</topic><topic>Drinking water</topic><topic>Drug dosages</topic><topic>Growth</topic><topic>Growth Plate - drug effects</topic><topic>Ketamine</topic><topic>Kidney - physiology</topic><topic>Kidney - surgery</topic><topic>Kidney diseases</topic><topic>Kidney Failure, Chronic - physiopathology</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Mineralization</topic><topic>Nephrectomy</topic><topic>Nephrology</topic><topic>Original Article</topic><topic>Osteoporosis</topic><topic>Parathyroid Hormone - blood</topic><topic>Pediatrics</topic><topic>Phosphates - blood</topic><topic>Phosphonates</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Uremia</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fischer, Dagmar-Christiane</creatorcontrib><creatorcontrib>Jensen, Claudia</creatorcontrib><creatorcontrib>Rahn, Anja</creatorcontrib><creatorcontrib>Salewski, Birgit</creatorcontrib><creatorcontrib>Kundt, Günther</creatorcontrib><creatorcontrib>Behets, Geert J.</creatorcontrib><creatorcontrib>D’Haese, Patrick</creatorcontrib><creatorcontrib>Haffner, Dieter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric nephrology (Berlin, West)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fischer, Dagmar-Christiane</au><au>Jensen, Claudia</au><au>Rahn, Anja</au><au>Salewski, Birgit</au><au>Kundt, Günther</au><au>Behets, Geert J.</au><au>D’Haese, Patrick</au><au>Haffner, Dieter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function</atitle><jtitle>Pediatric nephrology (Berlin, West)</jtitle><stitle>Pediatr Nephrol</stitle><addtitle>Pediatr Nephrol</addtitle><date>2011</date><risdate>2011</risdate><volume>26</volume><issue>1</issue><spage>111</spage><epage>117</epage><pages>111-117</pages><issn>0931-041X</issn><eissn>1432-198X</eissn><abstract>Bisphosphonates have been shown to attenuate ectopic calcification in experimental uremia. While they are known to reduce bone turnover, the effects on endochondral bone formation have not yet been addressed. To address this issue, we administered male Sprague-Dawley rats weekly subcutaneous injections of either vehicle or ibandronate (1.25 μg/kg body weight) for a total of 10 weeks. The rats were randomly allocated into one of four groups: (1) vehicle-treated, sham-operated rats; (2) ibandronate-treated, sham-operated rats; (3) vehicle-treated, 5/6 nephrectomized rats; (4) ibandronate-treated, 5/6 nephrectomized rats. Bones were double labeled with tetracycline and demeclocycline in vivo, and tibiae were removed for analysis. Weight gain was similar in all groups. Ibandronate reduced body length gain and tibial growth rate in the sham-operated animals but not in the rats showing chronic renal failure (CRF). The height of the proliferative zone of the epiphyseal growth plate was reduced in the ibandronate-treated controls and tended to be reduced in CRF rats. A significant correlation between tibial growth rate and height of the proliferative zone was observed. Mineral apposition rates were significantly reduced in ibandronate-treated, sham-operated rats and tended to be reduced in CRF rats. In conclusion, ibandronate interferes with tibial growth and bone mineralization in young rats with normal and reduced renal function.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>20953634</pmid><doi>10.1007/s00467-010-1660-5</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0931-041X |
| ispartof | Pediatric nephrology (Berlin, West), 2011, Vol.26 (1), p.111-117 |
| issn | 0931-041X 1432-198X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_814465049 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Animals Bisphosphonates Body weight Bone Density Conservation Agents - pharmacology Bone Development - drug effects Calcification Calcification, Physiologic - drug effects Calcium - blood Chronic kidney failure Diphosphonates - pharmacology Drinking water Drug dosages Growth Growth Plate - drug effects Ketamine Kidney - physiology Kidney - surgery Kidney diseases Kidney Failure, Chronic - physiopathology Male Medical research Medicine Medicine & Public Health Metabolism Mineralization Nephrectomy Nephrology Original Article Osteoporosis Parathyroid Hormone - blood Pediatrics Phosphates - blood Phosphonates Rats Rats, Sprague-Dawley Uremia Urology |
| title | Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A51%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibandronate%20affects%20bone%20growth%20and%20mineralization%20in%20rats%20with%20normal%20and%20reduced%20renal%20function&rft.jtitle=Pediatric%20nephrology%20(Berlin,%20West)&rft.au=Fischer,%20Dagmar-Christiane&rft.date=2011&rft.volume=26&rft.issue=1&rft.spage=111&rft.epage=117&rft.pages=111-117&rft.issn=0931-041X&rft.eissn=1432-198X&rft_id=info:doi/10.1007/s00467-010-1660-5&rft_dat=%3Cgale_proqu%3EA331348947%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1095597540&rft_id=info:pmid/20953634&rft_galeid=A331348947&rfr_iscdi=true |